



Strengthened preparedness and response
to biological and chemical terror attacks



Co-funded by
the Health Programme
of the European Union

Novel Threats

The dual-use risk of synthetic biology

Tone Bjordal Johansen

Senior Scientist, DVM, PhD

Department of Preparedness and Infection Prevention and Control
Norwegian Institute of Public Health
NORWAY


www.fhi.no

Tone.Johansen@fhi.no



JA TERROR

- Aims to address gaps in health preparedness and cross-sectoral work in response to biological and chemical threats
- Public health, law enforcement and civil protection organizations from 17 European countries.
- Coordinated by The Norwegian Directorate of Health



WP 1 – Coordination of the project

WP 2 – Dissemination of the project

WP 3 – Evaluation of the project

WP 4 – Sustainability and integration in national policies

WP 5 – Health preparedness & Response planning to biological and chemical terrorist attacks

WP 6 – Cross-sectoral collaboration: Law enforcement, Civil protection and Health

WP 7 – Risk and crisis communication (internal and public)

WP 8 – Novel threats

Norway

Belgium

Bulgaria

Czech Republic

Croatia

France

Germany

Greece

Hungary

Italy

Netherlands

Slovenia

Spain

Sweden

United Kingdom

Malta

Republic of Serbia

Synthetic biology



Photo: Colourbox



Concepts, approaches, and tools used to modify living organisms or to create new ones



Techniques and methods developed for beneficial purposes (new vaccines, medicines, gene therapy)




Can be adapted for malicious purposes
Dual-Use Research of Concern (DURC)

WP8: Novel threats

WP8: Health preparedness for novel threat agents, including synthetic biology, synthetic opioids and dual use technology.

- The consequences of biological threats can be equally serious regardless whether a disease is naturally occurring, accidental or intentional
- The COVID-19 pandemic demonstrated the enormous effects a pandemic can have worldwide
- Recent developments within synthetic biology cause growing concerns



WP8: Novel threats



Literature review to map and describe novel technologies (2016 - 2022)



Survey to evaluate existing knowledge, guidelines and regulations on dual-use aspects in EU




Risk- and recommendations-report

Results



Photo: Colourbox





Whole genome sequencing

Findings

- Most studies focused on beneficial aspects of using WGS and NGS in response to bioterrorism

Risks

- Publicly available databases, including genomes of highly virulent pathogens
- Potential misuse of sensitive genomic data

An official website of the United States government [Here's how you know](#)

NIH National Library of Medicine
National Center for Biotechnology Information Log in

i Some portions of our website are experiencing intermittent outages, and E-utilities requests may take longer than normal to complete. We apologize for the inconvenience and thank you for your patience as we resolve the issue.

GenBank

GenBank Submit Genomes WGS Metagenomes TPA TSA INSDC Documentation Other

GenBank Overview

What is GenBank?

GenBank[®] is the NIH genetic sequence database, an annotated collection of all publicly available DNA sequences ([Nucleic Acids Research, 2013 Jan;41\(D1\):D36-42](#)). GenBank is part of the [International Nucleotide Sequence Database Collaboration](#), which comprises the DNA DataBank of Japan (DDBJ), the European Nucleotide Archive (ENA), and GenBank at NCBI. These three organizations exchange data on a daily basis.

A GenBank release occurs every two months and is available from the [ftp site](#). The [release notes](#) for the current version of GenBank provide detailed information about the release and notifications of upcoming changes to GenBank. Release notes for [previous GenBank releases](#) are also available. GenBank growth [statistics](#) for both the traditional GenBank divisions and the WGS division are available from each release.

An [annotated sample GenBank record](#) for a *Saccharomyces cerevisiae* gene demonstrates many of the features of the GenBank flat file format.

GenBank Resources

- [GenBank Home](#)
- [Submission Types](#)
- [Submission Tools](#)
- [Search GenBank](#)
- [Update GenBank Records](#)



Genetic engineering (DNA synthesis, CRISPR/Cas, TALEN, Gibson Assembly etc)

Findings

- Several examples in relation to specific pathogens
 - Synthetic horsepox virus (Noyce, Lederman et al. 2018)
 - Outbreak strain of Ebola virus (McMullan, Flint et al. 2019)
 - Genetic modifications of *Yersinia pestis* (Wang et al., 2019)

Risks

- Editing microorganisms to increase their pathogenicity
- Modify to escape diagnostic assays
- Reconstruction of known pathogens
- Construction of new pathogens



Risks across technologies

Findings

- DIY-labs
- Availability of advanced technology at lower cost
 - Desktop DNA synthesizer and 3D printers
 - CRISPR bacterial gene editing kit

Risks

- Increased accessibility of technology and knowledge
- Lower cost and increased simplicity of use

**KILOBASER DNA & RNA
SYNTHESIZER**

YOUR FASTEST WAY TO DNA & RNA

Literature review

No examples of synthetic biology being used to cause harm

Several examples of synthetic biology being used to recreate or modify highly pathogenic agents

Publicly available databases, including genomes of highly virulent pathogens

Rapidly technological development, availability and lower cost.

Machine learning and artificial intelligence

Changing global CBRN threat landscape



Dual-use technology - desk review and questionnaire



A substantial number of guidance documents on the governance of dual-use is available

Export control regulation is often the only legal framework to control dual-use (EU Regulation 2021/821)

Biological Weapons Convention, Contained Use of Genetically Modified Organisms or import laws of biological materials

Many, but not all institutes and universities have, on a voluntary basis, implemented a system for the detection of potential dual-use risks

→ Develop a framework at EU level to comply with international regulations and guidance, to secure dual-use related risk mitigation

POTENTIAL CAUSES

Access to laboratories/
selected B agents
(biosecurity gaps)

- Biosecurity measures/ management (local level)
- Biosecurity guidance and regulations (national/ international level)

Access to molecular building blocks (DNA/ RNA sequences, kits)

- Dual-use measures (local level)
- Dual-use guidance and regulations (national/ international level)
- Screening of sequences and customers (DNA synthesis services and manufacturers)
- Implement traceability systems (DNA synthesis services and manufacturers)

Access to sensitive knowledge (how to increase virulence of pathogens, increase transmissibility, create de-novo agents)

- Risk assessment and ethical review of dual-use research at institutional level, also taking new technology into account (AI, ML)
- Risk assessment and ethical review of dual-use research at funding level, also taking new technology into account (AI, ML)
- Editorial policies for scientific journals
- Biosecurity screening of preprint servers

Access to technology (DIY labs, online kits, DNA synthesizers)

- Dual-use measures (local level)
- Dual-use guidance and regulations (national/ international level)
- Screening of customers
- Implement traceability and control systems of equipment

Access to data (DNA/ RNA databases etc)

- Dual-use measures (local level)
- Dual-use guidance and regulations (national/ international level)

Lack of awareness/ ignorance

- Education, training and awareness
- Regular exercises
- Regular risk assessment on dual-use
- Encouragement of culture of openness
- Engagement in professional societies

Lack of international collaboration and harmonization

- Enhance interdisciplinary cooperation at European and international levels
- Establish European biosecurity platform
- International cooperation building on existing initiatives
- Establish harmonized approach for risk assessment
- Develop strategies for surveillance and monitoring of synthetic biology threats

Lack of surveillance systems being able to detect and identify potential synthetic biology threats

- Epidemic intelligence
- Strengthen the capacity for rapid detection and identification of synthetic biology threats
- One Health approach on surveillance and monitoring

Actors with unethical intentions

- Intelligence
- Acceptance for reporting of suspicious behaviour / "whistle blowers"

PREVENTIVE MEASURES

Hazard:
Modified known pathogen or novel pathogen

Event:
Bioterror attack caused by misuse of synthetic biology

MITIGATION MEASURES

- Research, development and stockpiling of medical countermeasures including PPE
- Epidemic intelligence and surveillance
- Rapid detection and identification of synthetic biology threats
- Global notification systems/ warnings systems (IHR)
- National and international cross-sectoral collaboration*
- One Health approach on surveillance and monitoring

- One Health approach on surveillance and monitoring

- One Health approach on surveillance and monitoring

- Promote open and transparent communication among all stakeholders, including the public**

- Preparedness planning and regular exercises*
- National and international cross-sectoral collaboration*

Human disease, outbreaks/ epidemics/ pandemic

Animal disease/ outbreaks

Environmental consequences

Mistrust

Societal disruption and economic losses

CONSEQUENCES

*See recommendations on cross-sectoral collaboration by WP6: National and international cross-sectoral collaboration, Guiding Document (D6.5) and Preparedness planning and regular exercises, SimEx reports (D6.2) and (D6.6).

**See recommendations on risk communication by WP7: Biological and Chemical Terror Attacks: Risk and Crisis Communication Guidance Tool (D7.1) and Guidelines for Community Resilience at Major CB Health-Threats (D7.3)

PREVENTIVE MEASURES

MITIGATION MEASURES

POTENTIAL CAUSES



CONSEQUENCES



Risk mitigation strategies and recommendations

Established biosecurity measures not sufficient to prevent malicious use of synthetic biology

Interdisciplinary and intersectoral approach reaching all stakeholders



Control the spread of "know-how" and improve awareness



Access to technology and sensitive genomic data



Rapidly detect and identify synthetically engineered pathogens



Surveillance, intelligence gathering and threat assessment



Therapeutics/ vaccines



Oversight and governance frameworks



Thank you!

- Jessica Jones and Jackie Duggan (UK Health Security Agency; United Kingdom)
- Elisabeth H. Madslie (Norwegian Institute of Public Health; Norway)
- Didier Breyer (Sciensano; Belgium)
- Rik Bleijs (National Institute for Public Health and the Environment; the Netherlands)
- JA TERROR WP8 project working group

Joint Action TERROR has received funding from the European Union's Third Health Programme (2014–2020).

<https://www.jaterror.eu/>